Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

l mode of action, including its magnetic resonance imaging detectability, provides the opportunity for Xcytrin to be used in a broad range of cancers. In previously conducted randomized trials, Xcytrin combined with whole brain radiation therapy (WBRT) has been shown to prolong time to neurologic progression in patients with brain metastases from NSCLC. Xcytrin's non-overlapping toxicity makes it an appealing agent to use in combination with standard chemotherapy regimens.

The target for Xcytrin is the enzyme thioredoxin reductase, which is frequently overexpressed in lung cancer cells. This enzyme has been shown to confer to cancer cells characteristics of aggressive tumor growth and resistance to chemotherapy. First-line therapy for advanced NSCLC includes combination chemotherapy using drugs such as carboplatin, cisplatin, Gemzar(R), taxanes and others. Currently approved agents for second-line treatment of NSCLC include Alimta, Tarceva(R) and Taxotere.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. A New Drug Application for use of Xcytrin in combination with WBRT for treatment of brain metastases from NSCLC was filed with the Food and Drug Administration in April 2007. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. In addition, more information about advocacy on behalf of Xcytrin can be found at




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:9/19/2014)... 2014 Aufgrund der enormen ... erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die Jahre ... unter pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit ... Kraft treten. Für international tätige Unternehmen ... das "ob", sondern darum, "wann" sie die neu ...
(Date:9/19/2014)... , Sept. 19, 2014  CytRx Corporation (Nasdaq: ... company specializing in oncology, today announced that David ... at BioCentury,s 2014 NewsMakers in the Biotech Industry Conference on ... Time. The conference will take place at the Millennium ... . A live and archived webcast of ...
(Date:9/19/2014)...  PCI is pleased to announce it has ... leading provider of Clinical Trial Services and Temperature ... Wales in the United ... presence in the UK/EU to support global investigational ... and distribution capacity, as well as consultative services ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... WASHINGTON, Sept. 14, 2011 Labor and management in ... level to support increased protections to fight intellectual property ... to implement those protections." In a ... Pharmaceutical Industry Labor-Management Association ( PILMA ), the group ...
... Pa., Sept. 14, 2011 ECRI Institute ®, ... improving patient care, announces the release of PriceGuide ... advisory service for the procurement of medical-surgical supplies and ... "The 4.0 platform adds a whole new ...
Cached Medicine Technology:PILMA Vows to 'Redouble' Support for Increased Protections Against Intellectual Property Theft 2New PriceGuide 4.0 from ECRI Institute Helps Hospitals Rein in Supply Costs 2New PriceGuide 4.0 from ECRI Institute Helps Hospitals Rein in Supply Costs 3
(Date:9/20/2014)... (PRWEB) September 20, 2014 Villa del ... resort did not experience any damage in relation to ... and activities available. , Hurricane Odile struck Cabo San ... wind, rain and powerful surf conditions. Located on the ... Islands of Loreto experienced some heavy rain, but no ...
(Date:9/20/2014)... On Monday, September 22, Loma Linda ... research grant from Hyundai Hope on Wheels at a ... located on 11234 Anderson St., in Loma Linda. The ... Associate Professor at Loma Linda University and Director of ... children. , Loma Linda University Medical Center ...
(Date:9/20/2014)... (HealthDay News) -- The avian flu that killed 160 ... spread through respiratory drops and therefore poses a potential ... Although no human illnesses have been linked to the ... hospital have discovered natural mutations to the avian H3N8 ... the air in droplets. Current seasonal flu vaccines ...
(Date:9/20/2014)... New PharmaPoint Drug Evaluation report, ... 2023?. The asthma market saw very slow growth ... saturated with relatively efficacious standard therapies, such as ... and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and ... the launch of seven novel targeted biologic agents ...
(Date:9/20/2014)... NC (PRWEB) September 20, 2014 The excitement is ... in Mount Airy, North Carolina. This year the Surry Arts ... draws people from around the country who are still fans of ... Show is a sitcom that aired on CBS from 1960 through ... best show in American television history. Mount Airy, North Carolina ...
Breaking Medicine News(10 mins):Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 3Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 3Health News:Avian Flu In Harbor Seals Could Infect People 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2
... the primary cause of deaths from pneumonia in developing countries ... to a comprehensive new analysis to be released on Thursday, ... International Health , the authors estimate that two pneumococcal ... from the GAVI Alliance could save the lives of three ...
... -- The human jaw shrinks with age and that can result ... found. Swedish researchers looked at plaster molds made of the ... their 20s, and follow-up jaw molds of the same people made ... years there was less and less room for teeth in the ...
... Reporter , WEDNESDAY, Nov. 9 (HealthDay News) -- For the ... solid tumors, in this case non-small cell lung cancers. ... two had a complete response to therapy, one had a ... years after starting therapy. "It,s not a home run, ...
... new study released today offers hope that California may finally ... obesity, but it also showcases a patchwork of progress that ... in obesity rates among school-age children. According ... and Obesity Among California 5th, 7th and 9th Graders, 2005�," ...
... A clinical trial comparing prasugrel to clopidogrel for ... coronary intervention (PCI) was ended early due to relatively ... the primary endpoint at six month follow up. ... In patients underGoing elective stent placement on clopidogrel to ...
... Calif. With an estimated 1.5 million species, fungi represent ... Life . They have an enormous impact on human affairs ... and pathogens, and their partnership with host organisms for mutual ... an accurate understanding of what exactly they do, how they ...
Cached Medicine News:Health News:New studies show progress, value in vaccination against deadly pneumonia 2Health News:New studies show progress, value in vaccination against deadly pneumonia 3Health News:New studies show progress, value in vaccination against deadly pneumonia 4Health News:New Treatment May Boost Survival in Advanced Lung Cancer Cases 2Health News:New Treatment May Boost Survival in Advanced Lung Cancer Cases 3Health News:California making headway in battle against childhood obesity but successes are uneven 2Health News:Results of the TRIGGER-PCI trial reported at TCT 2011 2Health News:International team to sequence genomes of fungi 2Health News:International team to sequence genomes of fungi 3
UROSKOP Access, the dedicated urodiagnostic table with truly unrestricted patient access optimizes nearly all diagnostic and interventional procedures....
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
... therapeutic, expandable turning surface for the BariMaxx™ ... Prevention and treatment of pressure ulcers, Large ... patients using a statuc mattress that would ... whose body weight and size pose a ...
... The BariMaxx™ is a full-featured healthcare bed ... for the care and management of larger ... to 1000 lbs. ,Large patients at risk ... in excess of 1000 lbs. (including accessories), ...
Medicine Products: